Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4 + T cells in peritoneal space

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 1-13

  Kim, Jee Eun ^a   Jang, Min Ja ^a   Lee, Ji In ^a   Chung, Yoon Hee ^a   Jeong, Ji Hoon ^a   Hung, Chien Fu ^b,c   Kim, Daejin ^a,c  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

CD4; cisplatin; doxorubicin; MOSEC

Indexed keywords

CASPASE 3; CISPLATIN; DOXORUBICIN; INTERLEUKIN 10; INTERLEUKIN 12P40;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL; CARCINOGENESIS; CD4 LYMPHOCYTE COUNT; CELL THERAPY; DENDRITIC CELL; DOWN REGULATION; EPITHELIUM CELL; FEMALE; IMMUNE RESPONSE; IRRADIATION; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; NANOSTRUCTURES; OVARIAN NEOPLASMS; PERITONEUM;

EID: 84155163020     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182328569     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106-130.
2. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-156.
3. Laheru D, Biedrzycki B, Jaffee EM. Immunologic approaches to the management of pancreatic cancer. Cancer J. 2001; 7:324-337.
4. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21:624-630.
5. Berd D, Kairys J, Dunton C, et al. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998;25:646-653.
6. Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol. 2002;85:71-80.
7. Marsh S. Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int J Gynecol Cancer. 2009;19(Suppl 2):S30-S34.
8. Eralp Y, Wang X, Wang JP, et al. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6:R275-R283.
9. Tseng CW, Hung CF, Alvarez RD, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated anti-tumor immunity induced by DNA vaccination. Clin Cancer Res. 2008;14:3185-3192.
10. Kim D, Monie A, Tsai YC, et al. Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Ther. 2008;15:1176-1183.
11. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109:5346-5354.
12. Kim D, Hoory T, Monie A, et al. Delivery of chemother-apeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. J Biomed Sci. 2010;17:61.
13. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585-591.
14. Augey V, Cociglio M, Galtier M, et al. High-performance liquid chromatographic determination of cis-dichlorodiammi-neplatinum(II) in plasma ultrafiltrate. J Pharm Biomed Anal. 1995;13:1173-1178.
15. Bronchud MH, Margison JM, Howell A, et al. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1990;25:435-439.
16. Kim D, Hoory T, Wu TC, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther. 2007;18:1129-1139.
17. Fewell JG, Matar MM, Rice JS, et al. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med. 2009; 11:718-728.
18. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691-1701.
19. Tseng CW, Hung CF, Alvarez RD, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated anti-tumor immunity induced by DNA vaccination. Clin Cancer Res. 2008;14:3185-3192.
20. Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacoki-netics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977;37: 1416-1420.
21. Pruefer FG, Lizarraga F, Maldonado V, et al. Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J Chemother. 2008;20:348-354.
22. Zitvogel L, Casares N, Pequignot MO, et al. Immune response against dying tumor cells. Adv Immunol. 2004;84:131-179.
23. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science. 2004;305:197-200.
24. Sleijfer DT, Meijer S, Mulder NH. Cisplatin: a review of clinical applications and renal toxicity. Pharm Weekbl Sci. 1985;7:237-244.
25. Kawasaki K, Akashi S, Shimazu R, et al. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res. 2001;7:232-236.
26. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
27. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002; 20:2624-2632.
28. Disis ML, Goodell V, Schiffman K, et al. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol. 2004;24:571-578.
29. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobio-logy: from discovery to clinical applications. Adv Immunol. 2004;82:249-293.
30. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesothelio-mas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136-140.
31. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63:6076-6083.
32. Sandmaier BM, Oparin DV, Holmberg LA, et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother. 1999;22:54-66.
33. Hoffmann TK, Meidenbauer N, Dworacki G, et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000;60:3542-3549.
34. Shaif-Muthana M, McIntyre C, Sisley K, et al. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res. 2000;60:6441-6447.
35. Schnurr M, Scholz C, Rothenfusser S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 2002;62:2347-2352.
36. Sun L, Yi S, O'Connell PJ. IL-10 is required for human CD4(+)CD25(+) regulatory T cell-mediated suppression of xenogeneic proliferation. Immunol Cell Biol. 2010;88:612.
37. Chaudhry A, Samstein RM, Treuting P, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of th17 cell-mediated inflammation. Immunity. 2011;34:566-578.
38. Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011;52:3264-3271.
39. Kayashima H, Toshima T, Okano S, et al. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepato-cellular carcinoma in immunosuppressed mice. J Immunol. 2010;185:698-708.
40. Baxevanis CN, Voutsas IF, Tsitsilonis OE, et al. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol. 2000;164:3902-3912.
41. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129-144.
42. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358:2698-2703.